Report analyzes benefits, financing, R&D
activity and more to reveal emerging standouts in medical
science
United States
and Mainland China at the forefront of RNA technology
advancement
LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate
Plc (NYSE:CLVT), a global leader in providing trusted
information and insights to accelerate the pace of innovation,
today announced the release of a new report, RNA Technology
Companies to Watch. The report identifies seven emerging innovators
in the field of medical science who are solving for undruggable
disease targets. The report draws on data and analytics from
BioWorld, an award-winning suite of news services delivering
actionable intelligence on the most innovative therapeutics and
medical technologies in development, published by Clarivate.
Leveraging Clarivate and BioWorld data and insights paired with
analysis of drug benefits, financing, R&D activity and more,
this report explores what sets these companies apart and why they
are companies to watch.
With great potential to address unmet therapeutic needs,
therapies that act upon or incorporate RNA to fight disease have
gained traction over the last decade and were pushed into the
spotlight further with the regulatory approvals of mRNA vaccines
during the global COVID-19 pandemic. Success with rare diseases,
which typically do not respond well to traditional approaches, is
setting RNA therapies apart. Demonstrating benefits such as fewer
side effects and lower cost to enhanced efficacy and accessibility,
this emerging therapeutic modality is giving hope to patients and
clinicians.
However, RNA technologies present challenges, including the
innate limitations of instability, high innate immunogenicity and
challenges with targeted delivery, among other factors. Despite
these challenges, the space remains promising. In the report,
Clarivate has identified seven recently created innovative RNA
technology companies that are developing solutions to tackle
currently undruggable targets for undruggable targets within the
space, including:
- Aro Biotherapeutics— a company pioneering
the development of tissue-targeted genetic medicines with a
patented platform technology, Centyrin, positioned to precisely
target diverse therapeutics to specific cells of interest. Lead
programs include Centyrin-oligonucleotide conjugate therapies meant
to provide targeted delivery of oligonucleotides to extra-hepatic
tissues and Centryrin-small interfering (siRNA) conjugate therapies
for oncology targets.
- Cargene Biopharma Inc -- a company
developing highly specific, stable, potent, siRNA-based
oligonucleotide therapeutics via the company's OSCAR™ algorithm and
SMoP™ pharmacophore design platform. The company aims to address a
broad range of diseases, with an initial focus on liver and
ophthalmic disorders.
- DTx Pharma Inc -- a company that has
developed a proprietary platform technology called FALCON™ (Fatty
Acid Ligand Conjugated OligoNucleotide). The FALCON platform has
the potential to address multiple therapeutic areas, including CNS,
cardiovascular, immunology and oncology.
- HAYA Therapeutics SA -- a precision
therapeutics company that has developed a proprietary drug
discovery engine, DiscoverHAYA™️, enabling a pipeline of lead, long
non-coding RNA (lncRNA)-targeting, anti-fibrotic candidates for
many tissues including lung, kidney, liver and the solid tumor
microenvironment. The company's lead development candidate
(HTX-001) is a modified ASO targeting the lncRNA Wisper, a cardiac
myofibroblast-enriched driver of fibrosis.
- Laronde – a company
whose platform, Endless RNA™ (eRNA), involves novel,
closed-loop, programmable, persistent, non-immunogenic RNA
constructs to express therapeutic proteins inside the
body.
- Replicate Bioscience – a company designing
self-replicating (srRNA) immunotherapies with a primary focus on
drug resistance in oncology and new treatments for autoimmune and
inflammatory disorders. Lead candidates include RBI-1000 for breast
cancer, RBI-2000 for solid tumors, RBI-3000 for lung cancer and
RBI-8000 for inflammatory/autoimmune disease.
- Strand Therapeutics -- an emerging company developing
next-generation, programmable, long-acting mRNA therapeutics
capable of delivering precise, multi-functional, potentially
curative treatments with a single dose for cancer immunotherapy and
other diseases.
Mike Ward, Global Head of Life Sciences
and Healthcare Thought Leadership, Clarivate: "Success
with mRNA vaccines targeting COVID-19 has shone a spotlight on the
potential of RNA technologies for other diseases. Pharmaceutical
companies are now very keen to identify the next generation of
RNA-focused technologies that will deliver future medicines with
the potential to deliver better treatments."
Lynn Yoffee, Publisher,
BioWorld said: "Because RNA is known to directly regulate
important cellular processes, the misregulation of various
processes in diseases has led to an expanding level of research and
now many therapeutic strategies being pursued by these companies
and more. BioWorld has been tracking the launch and progression of
new biopharma firms for more than three decades and the development
timeline can be very long. But the speed with which mRNA technology
delivered vaccines to fight COVID-19, for example, highlights the
value of this technology. These seven firms are strong examples of
companies leveraging RNA to effectively treat a variety of
diseases."
The momentum of RNA technologies is apparent in the significant
increase in scientific knowledge, IP and deal-making value over
recent years. From 2010 to 2020, the number of patents filed
globally increased by 52%, and the number of RNA-related research
publications jumped by 160% between 2012 and
2021.1 In addition, the United States and Mainland China are at
the forefront of RNA technology advancement, with activity in
Mainland China accelerating. Of the top 20 organizations with
RNA-related patents globally, those based in Mainland China
accounted for 41% of the patents, followed by the United States
(40%).2 RNA companies need to
differentiate themselves in an increasingly crowded market by
identifying the addressable market to contribute to long-term
viability, ultimately maximizing patient benefit and commercial
success.
To learn more about the RNA Technology Companies to Watch
report, visit here.
For more Drugs to Watch updates and analyses throughout the
year, visit the Drugs to Watch web page and follow Clarivate
for Life Sciences & Healthcare Twitter and
LinkedIn.
Methodology for the RNA Technology Companies to Watch
Report
Clarivate analysts assessed the changing RNA landscape with a
variety of proprietary data sources,
including: BioWorld™, Cortellis Deals
Intelligence™, Derwent Innovation™, Web of
Science™ and other industry sources such as company
announcements, filings and peer-reviewed publications. Clarivate
experts and analysts weighted companies according to factors,
including: medical, business and scientific challenges these
companies are attempting to solve; patient unmet need and/or burden
of disease their solutions aim to address; whether the company has
demonstrated proof of concept and achieved key developmental
milestones; positioning in clinical trials; relationships with
notable scientific and academic institutions; financial
positioning, including funding secured, relationships with industry
and institutional investors, financial runway and prospects for
future fundraising or partnerships; and ownership and status of
intellectual property (IP) estate.
Please note that Clarivate generated data featured in this
report reflects findings prior to October
21, 2022. The RNA Technology Companies to Watch is based on
Clarivate's current expectations reflective of existing data, but
actual results derived from companies featured in the Report and
herein may differ.
About BioWorld
With writers and editors stationed around the
globe, BioWorld, published
by Clarivate, reports the breaking news – and provides
key perspective on hundreds of therapeutics and devices in
development, the companies behind those candidates, the business
development transactions that evolve the markets, and the
regulatory hurdles that both challenge and guard the
processes. BioWorld has a long tradition of excellence in
journalism. Collectively, the news services have been honored with
63 awards dating back to 1998, including 15 for its daily news
services.
Join the conversation and mention BioWorld
on Twitter and Clarivate for Life Sciences &
Healthcare on Twitter and LinkedIn.
About Clarivate
Clarivate™ is a global leader in providing solutions to
accelerate the pace of innovation. Our bold mission is to help
customers solve some of the world's most complex problems by
providing actionable information and insights that reduce the time
from new ideas to life-changing inventions in the areas of Academia
& Government, Life Sciences & Healthcare, Professional
Services and Consumer Goods, Manufacturing & technology. We
help customers discover, protect and commercialize their inventions
using our trusted subscription and technology-based solutions
coupled with deep domain expertise. For more information, please
visit clarivate.com.
1 Source: Web of Science™
2 Source: Derwent Innovation
Media contact:
Catherine
Daniel
Director External Communications, Life Sciences &
Healthcare
newsroom@clarivate.com
Logo -
https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/clarivate-identifies-seven-innovators-in-new-rna-technology-companies-to-watch-report-301658013.html